Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Off-the-shelf cellular therapy shows promise in the lab

Publish date:: December 8, 2019

Key clinical point: FT596 – a universal, anti-CD19 chimeric antigen receptor natural killer cell therapy derived from a master induced pluripotent stem cell line – has demonstrated activity against B-cell malignancies.

Major finding: FT596 reduced tumor growth in mouse models of leukemia and lymphoma. When combined with rituximab, FT596 was able to overcome CD19 antigen escape.

Study details: Preclinical research.

Disclosures: The research was conducted by employees of Fate Therapeutics, the company developing FT596.

Citation:

Goodridge JP et al. ASH 2019. Abstract 301.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

All Specialties